[Behavior of heparinocytes and fibrinolytic degradation products under sulfobromophthalein or indocyanine green in patients with liver diseases or persons with healthy liver].
Due to a slight haemooysis after the application of bromsulphalein an intravasal coagulation with reduction of the number of heparinocytes and an increase of fibrinolytic split products develops. These changes are to be observed in the vast majority of tests, also in such cases where no clinical signs of an incompatibility appear. Indocyanine-green does not cause these severe disturbances of coagulation. Slight changes are traced back to the examination technique. Patients with chronic liver disease already show increased values of fibrinolytic split products. In increased initial values of fibrinolytic split products bromsulphalein does not cause a further increase.
D000328:Adult; D002908:Chronic Disease; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D006493:Heparin / Q000378:metabolism*; D006801:Humans; D007208:Indocyanine Green / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects*; D008107:Liver Diseases / Q000175:diagnosis*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D012044:Regression Analysis; D013448:Sulfobromophthalein / Q000494:pharmacology*
D005338:Fibrin Fibrinogen Degradation Products; D013448:Sulfobromophthalein; D006493:Heparin; D007208:Indocyanine Green
Verhalten des Heparinozyten und der fibrinolytischen Spaltprodukte unter Bromsulfalein oder undozyaningrün bei leberkranken und lebergesunden Patienten